Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on June 9, 2025
Tired of the cryptocurrency hype? Join SIX MINING and earn passive income — without the guesswork!
GlobeNewswire
·
June 9, 2025
Washington, D.C, June 09, 2025 (GLOBE NEWSWIRE) -- The crypto market is full of hype, sudden pumps, and unpredictable dumps—like Trump Coin’s recent 7% jump that still can’t shake its overall bearish outlook. If you're tired of chasing trends and getting …
Free Mining with BCCMINING: Dogecoin, Bitcoin and Litecoin
GlobeNewswire
·
June 9, 2025
Atlanta, Georgia, June 09, 2025 (GLOBE NEWSWIRE) -- Free Mining with BCCMINING: Dogecoin, Bitcoin and Litecoin BCC Mining, a new member of the cryptocurrency community, recently launched a new mobile app, which is undoubtedly great news for cloud mining …
Earn Mining: Turn your phone into a mining machine, automatically earn BTC/DOGE/LTC every day, and obtain high fixed potential income through mobile cloud mining
GlobeNewswire
·
June 9, 2025
Vancouver, Canada, June 09, 2025 (GLOBE NEWSWIRE) -- With the rapid development of artificial intelligence, the wave of cryptocurrency has gradually swept the world. In this era driven by new technologies, traditional mining machines can no longer meet …
Alternative Investments Aren’t for Everyone
GlobeNewswire
·
June 9, 2025
LIVONIA, Mich., June 09, 2025 (GLOBE NEWSWIRE) -- Amid economic volatility and uncertainty, advisors are making noticeable adjustments to their portfolio strategies—particularly in their use of alternative investments (alts). While allocations to …
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
GlobeNewswire
·
June 9, 2025
FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts Up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data from SELVA expected in the first …
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
GlobeNewswire
·
June 9, 2025
Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 …
Ranchero Gold Announces Director Appointment
GlobeNewswire
·
June 9, 2025
VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Ranchero Gold Corp. (“Ranchero” or the “Company”) (TSX.V:RNCH) is pleased to announce the appointment of Andrew Wilson as an independent director of the Company and as chair of the Audit …
LeddarTech Enters into Further Amendments to Credit Facility and Bridge Financing Offer and Announces the Return to Work of Certain Employees Following Furlough
GlobeNewswire
·
June 9, 2025
QUEBEC CITY, Canada, June 09, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech” or the “Company”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software …
LeddarTech apporte d’autres modifications à sa facilité de crédit et à son offre de financement relais et annonce le retour au travail de certains employés mis à pied
GlobeNewswire
·
June 9, 2025
QUÉBEC, Canada, 09 juin 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (« LeddarTech » ou la « Société ») (Nasdaq : LDTC), une société de logiciels automobiles qui fournit des technologies logicielles de fusion bas niveau de capteurs et de perception …
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
GlobeNewswire
·
June 9, 2025
D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions. The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in …
Alarum Technologies Updates Second Quarter 2025 Revenue and Adjusted EBITDA Outlook
GlobeNewswire
·
June 9, 2025
TEL AVIV, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced an update to its revenue and Adjusted EBITDA outlook for the …
Outbrain Completes Change of Corporate Name to Teads
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Outbrain Inc. (NASDAQ: OB), which is operating under the new Teads brand following Outbrain’s acquisition of Teads in February 2025, announced today that the combined company has completed its corporate renaming …
Oddity Finance LLC Announces Proposed $350 Million Offering of 0% Exchangeable Senior Notes Due 2030
GlobeNewswire
·
June 9, 2025
As of March 31, 2025, ODDITY had $257 million in cash, and an undrawn $200 million credit line Capital raise gives ODDITY additional firepower to play offense and pursue future opportunities in a volatile world A portion of the proceeds will be used to …
George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment
GlobeNewswire
·
June 9, 2025
Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy, with an established safety profile and good tolerability First and only triple combination for the initial …
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
GlobeNewswire
·
June 9, 2025
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity …
G2 Drills Multiple Near Surface Intercepts in New Oko Discovery Area, Significant Sulphide Mineralization Encountered in Deeper Drill Holes
GlobeNewswire
·
June 9, 2025
Hole AMD18 returns 65m @ 1.5 g/t Au & 9.7m @ 3.1 g/t Au Hole AMD23 returns 52m @ 0.9 g/t Au Hole AMD25 intercepts 70.5m @ 1.8 g/t Au New Oko discovery total strike length of 630m; remains open in all directions TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- G2 …
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
GlobeNewswire
·
June 9, 2025
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p<0.002) and in ApoE4 …
Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma
GlobeNewswire
·
June 9, 2025
SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that the first patient has been dosed in its Phase 3 TERZO …
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
GlobeNewswire
·
June 9, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a …
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of …